"The annual J.P. Morgan Healthcare Conference draws the attention of much of the healthcare industry, making the event a popular time to announce deals. Acquisition announcements were not as prolific this year. Outside of a Boston Scientific buyout, no major M&A deals were unveiled during the conference. Perhaps that's because so many acquisitions were announced as 2025 drew to a close."
"The sentiment of conferencegoers was optimistic, with some citing the IPO of Aktis Oncology as a possible sign of a reopening biotech IPO market. Financing activity is also picking up for startups, and many of them timed new financing announcements for JPM week. While most of the rounds were for clinical-stage companies, the financings also include some seed-stage companies, which could turn the tide of slowing seed and early-stage venture activity reported by J.P. Morgan in its Q4 2025 Biopharma and Licensing Report."
"-Caldera Therapeutics launched, revealing $112.5 million raised to date to support CLD-423, a bispecific antibody in early clinical development for inflammatory bowel disease and other immunologic and inflammatory disorders. The funding breaks down to a $75 million Series A round from investors Atlas Venture, LAV, and venBio. Most recently, the Cambridge, Massachusetts-based startup said it had closed $37.5 million in Series A-1 financing led by Omega Funds."
The J.P. Morgan Healthcare Conference featured optimistic sentiment but fewer acquisition announcements, with only a Boston Scientific buyout noted. The IPO of Aktis Oncology served as a possible sign of a reopening biotech IPO market. Startup financing activity picked up around JPM week, with many companies timing new financings to the event. Most rounds targeted clinical-stage companies, while some seed-stage financings could help counter recent declines in early-stage venture activity. Caldera Therapeutics launched with $112.5 million to support CLD-423, and Mirador Therapeutics closed a $250 million Series B to advance clinical programs with multiple expected readouts by 2027.
Read at MedCity News
Unable to calculate read time
Collection
[
|
...
]